Outside of ovarian cancer, olaparib is also approved for metastatic germline BRCA mutant HER2-negative breast cancer that has been previously treated with chemotherapy, first-line maintenance in germline BRCA mutant pancreatic adenocarcinoma and HRR gene mutated metastatic castration resistant prostate cancer 30. The gene discussed is ERBB2; the disease is ovarian carcinoma.